复方丹参滴丸联合舒血宁治疗冠心病心绞痛的临床分析

An analysis of treating CHD angina pectoris with Fufang Danshen Diwan plus Shuxuening

目的:探讨对冠状动脉粥样硬化性心脏病(简称冠心病)心绞痛患者选择复方丹参滴丸联合舒血宁治疗后获得的临床效果。方法:选择我院2016年10月-2019年2月收治的60例冠心病心绞痛患者作为实验对象;数字奇偶法分组后探究每组所用药物。比照组(30例)选择舒血宁展开疾病治疗;实验组(30例)选择复方丹参滴丸联合舒血宁展开疾病治疗;比较治疗效果。结果:实验组冠心病心绞痛患者心绞痛总有效率明显高于比照组(P<0.05);实验组冠心病心绞痛患者心电图总有效率明显高于比照组(P<0.05);实验组冠心病心绞痛患者心绞痛发作次数少于比照组明显(P<0.05);实验组冠心病心绞痛患者C反应蛋白(C-reactive Protein,CRP)、白细胞计数(White Blood Cell,WBC)以及纤维蛋白原(Fibrinogen,FIB)水平均低于比照组明显(P<0.05);治疗前,实验组冠心病心绞痛患者中医症状积分同比照组比较差异不明显(P>0.05);治疗后,实验组中医症状积分明显低于比照组(P<0.05);治疗前,实验组冠心病心绞痛患者内皮素(Endothelin,ET)水平以及一氧化氮(Nitric Oxide,NO)水平同比照组比较差异不明显(P>0.05);治疗后,实验组ET水平低于比照组明显,NO水平高于比照组明显(P<0.05)。结论:冠心病心绞痛患者于临床接受复方丹参滴丸联合舒血宁治疗后,对于用药效果提升,心绞痛发作次数的减少,CRP、WBC以及FIB水平的降低,效果明显,最终对于冠心病心绞痛患者病情康复,奠定基础。

To explore efficacy of Fufang Danshen Diwan(复方丹参滴丸)plus Shuxuening(舒血宁)on CHD angina pectoris.Methods:60 cases of CHD angina pectoris in our hospital from October 2016 to February 2019 were admitted,and were divided into two groups according to parity number.The control group(30 cases)was treated with Shuxuening,and the experiment group(30 cases)was treated with Fufang Danshen Diwan plus Shuxuening.Results:Total efficiency and electrocardiographic efficiency in the experiment group were higher than those in the control group(P<0.05).Frequency of angina attacks in the experiment group was fewer than the control group(P<0.05).CRP,WBC and FIB level in the experiment group were lower than those in the control group(P<0.05).After treatment,TCM symptom score in the experiment group was fewer than that in the control group(P<0.05).After treatment,ET in the experiment group was lower than that in the control group(P<0.05),and NO level in the experiment group was higher than that in the control group(P<0.05).Conclusion:Fufang Danshen Diwan plus Shuxuening was effective on CHD angina pectoris,and can decrease frequency of angina attacks,CRP,WBC and FIB.